Alpha Cognition Inc ACOGF

Primary Symbol: C.ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

CSE:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by culturedpiggy01on Jan 13, 2022 3:54pm

77 Views

Post# 34314380

$ACOG.v welcomes Jami Rogers as Director of Marketing

$ACOG.v has welcomed Jami Rogers as their Director of Marketing. Her focus will moving forward with the commercialization of ALPHA-1062.

ALPHA-1062 is a prodrug of an approved AChEl (acetylcholinesterase inhibitor). The drug was designed specifically to combat commonly occurring side-effects of other AChEls. Learn more about the drug here: https://www.alphacognition.com/our-approach/alpha-1062/

td, $ACOG.v trading at $1.03 with market cap at $63.34 M

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition